Summary
Pfizer Inc. (PFE) announced on December 7, 2017, a series of significant debt management transactions. These include a private offer to exchange its outstanding £1.5 billion 6.500% Notes due 2038 for new debt securities, alongside an offer to purchase these same 2038 Notes for cash. The company is also initiating a cash tender offer for its outstanding €2 billion 5.750% Notes due 2021, coupled with a consent solicitation to amend the terms of these 2021 Notes and their governing indenture.
Key Highlights
- 1Pfizer is proactively managing its debt portfolio through exchange offers and cash tender offers.
- 2The company is seeking to refinance its outstanding £1.5 billion 6.500% Notes due 2038.
- 3Pfizer is also making an offer to purchase its €2 billion 5.750% Notes due 2021 for cash.
- 4A consent solicitation is underway for the 2021 Notes to amend terms and the associated indenture.
- 5These transactions are detailed in an Offering Memorandum, Offer to Purchase, and Consent Solicitation Statement.
- 6The transactions were announced via a press release filed as an exhibit to the 8-K.